N-benzyloxycarbonyl-cis-4-hydroxy-L-prolinol | 1009335-39-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyloxycarbonyl-cis-4-hydroxy-L-prolinol
• 英文别名: (2R,4R)-benzyl 4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate；benzyl (2R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate
• CAS: 1009335-39-0
• 化学式: C₁₃H₁₇NO₄
• 分子量: 251.282
• InChiKey: WDEQGLDWZMIMJM-VXGBXAGGSA-N

物化性质

• 沸点：
  433.9±40.0 °C(Predicted)
• 密度：
  1.297±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  70
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  N-benzyloxycarbonyl-cis-4-hydroxy-L-prolinol 在 10% Pd on charcoal 、 氢气 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 20.0 ℃ 、68.95 kPa 条件下， 反应 12.0h， 以98%的产率得到cis-4-hydroxy-L-prolinol
  参考文献：
  名称：

  基于脯氨醇的核苷膦酸：新的等构构型灵活的核苷酸类似物

  摘要：

  反式-4-羟基-1-脯氨酸已经用作合成基于脯氨醇的核苷酸类似物的起始原料，该核苷酸类似物具有与脯氨醇环氮原子连接的N-膦酰基甲基部分。基于在1-和4-位上的构型反转的合成方法学导致所有非对映异构的O-保护的4-甲磺酰脯氨醇-N-膦酸酯。使用合成子在核碱基的烷基化升-series得到对应于α-核苷酸类似物升-和β-升个核苷酸。在两个不同的pH值下进行的在水溶液中的这些化合物的基于NMR的构象的研究中，示出了任一Ñ-完全质子化或去质子化的形式，揭示了在两种情况下都出现了相同的，大部分为种群的构象体。测试了所有最终的基于1-脯氨醇的核苷膦酸的细胞毒性和抗病毒特性，但未发现明显的活性。

  DOI：

  10.1016/j.tet.2008.11.035
• 作为产物：
  描述：

  顺式-4-羟基-D-脯氨酸 在 锂硼氢 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 N-benzyloxycarbonyl-cis-4-hydroxy-L-prolinol
  参考文献：
  名称：

  Ceulemans, G.; Aerschot, A. Van; Herdewijn, P., Collection of Czechoslovak Chemical Communications, 1996, vol. 61, p. S234 - S237

  摘要：

  DOI：

文献信息

• Structure guided design of a series of sphingosine kinase (SphK) inhibitors
  作者：Darin J. Gustin、Yihong Li、Matthew L. Brown、Xiaoshan Min、Mike J. Schmitt、Malgorzata Wanska、Xiaodong Wang、Richard Connors、Sheere Johnstone、Mario Cardozo、Alan C. Cheng、Shawn Jeffries、Brendon Franks、Shyun Li、Shanling Shen、Mariwil Wong、Holger Wesche、Guifen Xu、Timothy J. Carlson、Matthew Plant、Kurt Morgenstern、Karen Rex、Joanna Schmitt、Angela Coxon、Nigel Walker、Frank Kayser、Zhulun Wang

  DOI：10.1016/j.bmcl.2013.06.030

  日期：2013.8

  inhibition of both isoforms is likely required to block SphK dependent angiogenesis. A structure based approach was used to design and synthesize a series of SphK inhibitors resulting in the identification of the first potent inhibitors of both isoforms of human SphK. Additionally, to our knowledge, this series of inhibitors contains the only sufficiently potent inhibitors of murine SphK1 with suitable

  鞘氨醇-1-磷酸（S1P）信号在有丝分裂，细胞迁移和血管生成中起着至关重要的作用。鞘氨醇激酶（SphKs）催化鞘磷脂代谢中的关键步骤，从而导致S1P的产生。SphK有两种同工型，对SphK缺陷小鼠的观察表明，这两种同工型可以弥补彼此的损失。因此，可能需要抑制两种同工型才能阻断SphK依赖性血管生成。基于结构的方法用于设计和合成一系列SphK抑制剂，从而鉴定出人类SphK两种同工型的第一种有效抑制剂。此外，据我们所知，
• Structure-Guided Minimalist Redesign of the L-Fuculose-1-Phosphate Aldolase Active Site: Expedient Synthesis of Novel Polyhydroxylated Pyrrolizidines and their Inhibitory Properties Against Glycosidases and Intestinal Disaccharidases
  作者：Xavier Garrabou、Livia Gómez、Jesús Joglar、Sergi Gil、Teodor Parella、Jordi Bujons、Pere Clapés

  DOI：10.1002/chem.201000714

  日期：2010.9.17

  L‐fuculose‐1‐phosphate aldolase from E. coli FucA was envisaged, to extend its tolerance towards bulky and conformationally restricted N‐Cbz‐amino aldehyde acceptor substrates (Cbz=benzyloxycarbonyl). Various mutants at the active site of the FucA wild type were obtained and screened with seven sterically demanding N‐Cbz‐amino aldehydes including N‐Cbz‐prolinal derivatives. FucA F131A showed an aldol activity of

  设想了对来自大肠杆菌FucA的L-岩藻糖-1-磷酸醛缩酶的最小活性位点重新设计，以扩展其对庞大且构象受限的N -Cbz-氨基醛受体底物（Cbz =苄氧基羰基）的耐受性。获得了FucA野生型活性位点的各种突变体，并用7种空间需求的N -Cbz-氨基醛（包括N -Cbz-脯氨酸衍生物）进行了筛选。FucA F131A显示具有（R）‐ N的醛醇活性为62μmolh -1  mg -1-Cbz-脯氨酸，而在FucA野生型中未观察到可检测的活性。对于其他底物，F131A突变体的羟醛酶活性比野生型FucA高4至25倍。关于反应的立体化学，（R）-氨基醛仅产生抗构型的羟醛加合物，而它们的S对应物给出反/顺非对映异构体的可变比例。有趣的是，F131A突变体对（R）-和（S）-N -Cbz-脯氨酸均具有高度立体选择性，仅产生抗和合成醛醇加合物分别。分子模型表明，这种改进的对大体积和刚性更大的底物（例如氮）的
• Aza-benzofuranyl compounds and methods of use
  申请人：Savy Pierre Pascal

  公开号：US20080085886A1

  公开（公告）日：2008-04-10

  The invention relates to azabenzofuranyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及具有抗癌和/或抗炎活性的Formula I的氮杂苯并呋喃化合物，更具体地涉及抑制MEK激酶活性的氮杂苯并呋喃化合物。本发明提供了用于抑制异常细胞生长或治疗哺乳动物的增生性疾病或治疗炎症性疾病的组合物和方法。本发明还涉及使用该化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• WO2008/24725
  申请人：——

  公开号：——

  公开（公告）日：——
• Oligonucleotide Analogues with 4-Hydroxy-N-Acetylprolinol as Sugar Substitute
  作者：Griet Ceulemans、Arthur Van Aerschot、Berthold Wroblowski、Jef Rozenski、Chris Hendrix、Piet Herdewijn

  DOI：10.1002/chem.19970031215

  日期：1997.12

  AbstractModified oligonucleotides incorporating trans‐4‐hydroxy‐N‐acetyl‐L‐prolinol (trans‐4‐HO‐L‐NAP) or its D‐analogue as sugar substitute were synthesised with adenine and thymine as nucleobases. All‐adenine oligonucleotides built from (2S,4S) or (2R,4R)‐cis‐4‐hydroxy‐N‐acetylprolinol were likewise prepared. Hybridisation studies revealed that heterocomplexes formed between polyU and homochiral trans‐4‐hydroxy‐N‐acetylprolinol‐based oligomers of the same as well as of opposite chirality (polyU/trans‐DA*13 and polyU/trans‐LA*13). The former, however, were triple‐stranded. Other complexes with ribonucleic acids were polyA/trans‐LT*13 and polyU/cis‐LA*13. Heteroduplexes with deoxynucleic acids were formed between trans‐LA*13 and oligothymidylate. Interaction was also observed for cis‐LA*13 and oligothymidylate, but not with the D‐hydroxyprolinol analogues. Microcalorimetry proved this interaction to be the formation of a triple‐stranded complex. Two heteroduplexes, trans‐LA*13/dT13 and trans‐LA*13/polyU, had similar or slightly increased stability when compared to the natural dA13/dT13 or dA13/polyU systems. Microcalorimetry clearly indicated the formation of a duplex, in contrast to interactions with N‐acetylprolinol oligonucleotides of different stereochemistry. Moreover, the enthalpy change was of the same magnitude but the association constant was slightly lower. Natural nucleic acids thus clearly prefer hybridisation with L‐hydroxyprolinol oligomers over D‐hydroxyprolinol oligomers. For the series investigated, the L‐trans oligomers (Figure 1) seem best to mimic natural oligonucleotides. These modified oligonucleotides formed homocomplexes if both strands were of the same chirality, that is, homocomplexes formed between trans‐LA* and trans‐LT* and between trans‐DA* and trans‐DT*, reflecting the isochiral pu‐py pairing found in natural nucleic acids. Once more, however, calorimetry proved these to be triplex interactions. Heterochiral pairing was not observed between modified oligonucleotides, but only between modified oligonucleotides and natural polyU. The thermal stabilities of these heterochiral complexes differed clearly.